ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44 :350–356.
-
2
Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD, 1994. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51 :77–82.
-
3
Llanos-Cuentas A, Echevaria J, Cruz M, La Rosa A, Campos M, Franke E, Berman J, Modabber F, Marr J, 1997. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 25 :677–684.
-
4
Romero GA, Lessa HA, Orge MG, Macêdo VO, Marsden PD, 1998. Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow up. Rev Soc Bras Med Trop 31 :511–516.
-
5
Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ, 2008. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52 :2855–2860.
-
6
Oliveira-Neto MP, Mattos M, Pirmez C, de Sousa CFS, Junior GG, 2000. Mucosal leishmaniasis (espundia) responsive to low dose of n-methyl glucamine (glucantime) in Rio de Janeiro, Brazil. Rev Inst Med Trop São Paulo 42: 321–325.
-
7
Machado PR, Lessa H, Lessa M, Guimarães LH, Bang H, Ho JL, Carvalho EM, 2007. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44 :788–793.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1604 | 1503 | 33 |
| Full Text Views | 322 | 10 | 0 |
| PDF Downloads | 86 | 7 | 0 |
Efficacy of Extended (Six Weeks) Treatment with Miltefosine for Mucosal Leishmaniasis in Bolivia
Jaime Soto
Jaime Soto
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland
Search for other papers by Jaime Soto in
Current site
Google Scholar
PubMed
Search for other papers by Jaime Soto in
Current site
Google Scholar
PubMed
Jaime Rea
Jaime Rea
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland
Search for other papers by Jaime Rea in
Current site
Google Scholar
PubMed
Search for other papers by Jaime Rea in
Current site
Google Scholar
PubMed
Margarita Valderrama
Margarita Valderrama
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland
Search for other papers by Margarita Valderrama in
Current site
Google Scholar
PubMed
Search for other papers by Margarita Valderrama in
Current site
Google Scholar
PubMed
Julia Toledo
Julia Toledo
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland
Search for other papers by Julia Toledo in
Current site
Google Scholar
PubMed
Search for other papers by Julia Toledo in
Current site
Google Scholar
PubMed
Luis Valda
Luis Valda
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland
Search for other papers by Luis Valda in
Current site
Google Scholar
PubMed
Search for other papers by Luis Valda in
Current site
Google Scholar
PubMed
Jaime Ardiles
Jaime Ardiles
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland
Search for other papers by Jaime Ardiles in
Current site
Google Scholar
PubMed
Search for other papers by Jaime Ardiles in
Current site
Google Scholar
PubMed
Jonathan Berman
Jonathan Berman
Centro de Investigaciones Bioclínicas de la Fundación FADER, Bogotá, Colombia; Proyecto Obras Sociales de Caminos de Acceso Rur, Palos Blancos, Bolivia; Departamento Médico, Hospital de Clínicas, La Paz, Bolivia; Servicio de Otorrinolaringología, Hospital de Clínicas, La Paz; Fast-Track Drugs and Biologics LLC, North Potomac, Maryland
Search for other papers by Jonathan Berman in
Current site
Google Scholar
PubMed
Search for other papers by Jonathan Berman in
Current site
Google Scholar
PubMed
We investigated whether increasing the period of follow-up or increasing the duration of therapy would markedly alter the 71% cure rate of mucosal leishmaniasis in Bolivia consequent to treatment with miltefosine for 4 weeks. Increasing the follow-up from 12 months to 24 months demonstrated additional relapse in only 2 of 41 patients. Increasing the period of therapy from 4 weeks to 6 weeks only increased the cure rate to 75%. The cure rate of mucosal leishmaniasis in Bolivia, whether 4 or 6 weeks of therapy is used and whether 12 month or 24 months follow up is conducted, is approximately 70%.
Author Notes
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
Soto J, Toledo J, Valda L, Balderrama M, Rea I, Parra R, Ardiles J, Soto P, Gomez A, Molleda F, Fuentelsaz C, Anders G, Sindermann H, Engel J, Berman J, 2007. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 44 :350–356.
-
2
Franke ED, Llanos-Cuentas A, Echevarria J, Cruz ME, Campos P, Tovar AA, Lucas CM, Berman JD, 1994. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 51 :77–82.
-
3
Llanos-Cuentas A, Echevaria J, Cruz M, La Rosa A, Campos M, Franke E, Berman J, Modabber F, Marr J, 1997. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 25 :677–684.
-
4
Romero GA, Lessa HA, Orge MG, Macêdo VO, Marsden PD, 1998. Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow up. Rev Soc Bras Med Trop 31 :511–516.
-
5
Dorlo TP, van Thiel PP, Huitema AD, Keizer RJ, de Vries HJ, Beijnen JH, de Vries PJ, 2008. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 52 :2855–2860.
-
6
Oliveira-Neto MP, Mattos M, Pirmez C, de Sousa CFS, Junior GG, 2000. Mucosal leishmaniasis (espundia) responsive to low dose of n-methyl glucamine (glucantime) in Rio de Janeiro, Brazil. Rev Inst Med Trop São Paulo 42: 321–325.
-
7
Machado PR, Lessa H, Lessa M, Guimarães LH, Bang H, Ho JL, Carvalho EM, 2007. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44 :788–793.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1604 | 1503 | 33 |
| Full Text Views | 322 | 10 | 0 |
| PDF Downloads | 86 | 7 | 0 |